**Question:** When heparin is given in pregnancy, which of the following is to be added?

**Core Concept:** Heparin is an antithrombin drug used to prevent and treat thrombosis. It works by inhibiting the activation of factor Xa and thrombin, preventing the clotting cascade from progressing.

**Why the Correct Answer is Right:** Heparin is primarily used as an anticoagulant during pregnancy to prevent and manage thromboembolic events like deep vein thrombosis (DVT) and pulmonary embolism (PE). It is crucial to monitor its anticoagulant effect by measuring activated partial thromboplastin time (aPTT) or activated clotting time (ACT). Regular monitoring ensures that the therapeutic window is maintained, avoiding excessive anticoagulation (bleeding complications) or insufficient anticoagulation (thrombosis).

**Why Each Wrong Option is Incorrect:**

A. Monitoring clotting time (PT/INR): PT/INR is not specific to heparin and is influenced by vitamin K-dependent clotting factors, which are not directly affected by heparin. It is not recommended for monitoring heparin therapy.

B. Monitoring platelet count: Heparin does not affect platelet function or count, so monitoring platelets is not relevant in heparin therapy.

C. Monitoring fibrinogen level: Heparin directly affects fibrinogen, which is incorrect. Monitoring fibrinogen can lead to misinterpretation of heparin's effect.

D. Adding unfractionated heparin: Unfractionated heparin is a different anticoagulant with a different dosing regimen compared to low molecular weight heparin (LMWH) used in pregnancy. Therefore, adding unfractionated heparin is incorrect.

**Correct Answer:** Adding an antiplatelet agent (e.g., aspirin) alongside heparin.

**Why the Correct Answer is Right:** In pregnancy, a combination of heparin and an antiplatelet agent like aspirin is often used to prevent preeclampsia, placental abruption, and fetal growth restriction. The combination helps to modulate the dual pathways of platelet activation and inflammation to reduce the risk of adverse maternal and fetal outcomes.

**Why Each Wrong Option is Incorrect:**

A. Adding a vitamin K antagonist: Vitamin K antagonists (e.g., warfarin) are used for different indications (e.g., stroke prevention) and have distinct pharmacokinetics and pharmacodynamics compared to heparin. Adding warfarin would be incorrect for the prevention of thromboembolic events in pregnancy.

B. Adding a direct oral anticoagulant (DOAC): Direct oral anticoagulants (e.g., dabigatran, rivaroxaban, or apixaban) are also used for different indications (e.g., atrial fibrillation, deep vein thrombosis) and have distinct pharmacodynamics compared to heparin. Adding a DOAC would be incorrect for the prevention of thromboembolic events in pregnancy.

C. Adding